Terms: = Head and neck cancer AND CDC73, HRPT2, 79577, ENSG00000134371, HPT-JT, Q6P1J9, FLJ23316, C1orf28 AND Prognosis
17 results:
1. Parathyroid carcinoma: molecular therapeutic targets.
Marini F; Giusti F; Palmini G; Aurilia C; Donati S; Brandi ML
Endocrine; 2023 Sep; 81(3):409-418. PubMed ID: 37160841
[TBL] [Abstract] [Full Text] [Related]
2. Clinical and genetic analysis of atypical parathyroid adenoma compared with parathyroid carcinoma and benign lesions in a Chinese cohort.
Chen Y; Song A; Nie M; Jiang Y; Li M; Xia W; Wang O; Xing X
Front Endocrinol (Lausanne); 2023; 14():1027598. PubMed ID: 36777354
[TBL] [Abstract] [Full Text] [Related]
3. Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma.
Makino H; Notsu M; Asayama I; Otani H; Morita M; Yamamoto M; Yamauchi M; Nakao M; Miyake H; Araki A; Uchino S; Kanasaki K
Intern Med; 2022 Nov; 61(22):3383-3390. PubMed ID: 35370235
[TBL] [Abstract] [Full Text] [Related]
4. Genetics and Epigenetics of Parathyroid Carcinoma.
Marini F; Giusti F; Palmini G; Perigli G; Santoro R; Brandi ML
Front Endocrinol (Lausanne); 2022; 13():834362. PubMed ID: 35282432
[TBL] [Abstract] [Full Text] [Related]
5. Do Patients With Atypical Parathyroid Adenoma Need Close Follow-up?
Saponaro F; Pardi E; Mazoni L; Borsari S; Torregrossa L; Apicella M; Frustaci G; Materazzi G; Miccoli P; Basolo F; Marcocci C; Cetani F
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4565-e4579. PubMed ID: 34157106
[TBL] [Abstract] [Full Text] [Related]
6. Parathyroid cancer: An update.
Rodrigo JP; Hernandez-Prera JC; Randolph GW; Zafereo ME; Hartl DM; Silver CE; Suárez C; Owen RP; Bradford CR; Mäkitie AA; Shaha AR; Bishop JA; Rinaldo A; Ferlito A
Cancer Treat Rev; 2020 Jun; 86():102012. PubMed ID: 32247225
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic role of parafibromin staining and cdc73 mutation in patients with parathyroid carcinoma: A systematic review and meta-analysis based on individual patient data.
Zhu R; Wang Z; Hu Y
Clin Endocrinol (Oxf); 2020 Apr; 92(4):295-302. PubMed ID: 31945198
[TBL] [Abstract] [Full Text] [Related]
8. Long-term remission of disseminated parathyroid cancer following immunotherapy.
Sarquis M; Marx SJ; Beckers A; Bradwell AR; Simonds WF; Bicalho MAC; Daly AF; Betea D; Friedman E; De Marco L
Endocrine; 2020 Jan; 67(1):204-208. PubMed ID: 31782130
[TBL] [Abstract] [Full Text] [Related]
9. MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma.
Guan L; Li T; Ai N; Wang W; He B; Bai Y; Yu Z; Li M; Dong S; Zhu Q; Ding XX; Zhang S; Li M; Tang G; Xia X; Zhao J; Lin S; Yao S; Zhang L; Chen G; Liu FE; Li X; Zhang H
J Exp Clin Cancer Res; 2019 Oct; 38(1):417. PubMed ID: 31623651
[TBL] [Abstract] [Full Text] [Related]
10. Circular RNA profile of parathyroid neoplasms: analysis of co-expression networks of circular RNAs and mRNAs.
Hu Y; Zhang X; Cui M; Wang M; Su Z; Liao Q; Zhao Y
RNA Biol; 2019 Sep; 16(9):1228-1236. PubMed ID: 31213128
[TBL] [Abstract] [Full Text] [Related]
11. [Clinical and morphological characteristics of parathyroid carcinoma].
Voronkova IA; Mokrysheva NG; Kazantseva IA; Gurevich LE
Arkh Patol; 2018; 80(4):65-72. PubMed ID: 30059074
[TBL] [Abstract] [Full Text] [Related]
12. Parathyroid carcinoma: a clinical and genetic perspective.
Cetani F; Pardi E; Marcocci C
Minerva Endocrinol; 2018 Jun; 43(2):144-155. PubMed ID: 28949121
[TBL] [Abstract] [Full Text] [Related]
13. The roles of parafibromin expression in ovarian epithelial carcinomas: a marker for differentiation and prognosis and a target for gene therapy.
Shen DF; Liu X; Yang XF; Fang L; Gao Y; Zhao S; Wu JC; Shi S; Li JJ; Zhao XX; Gou WF; Zheng HC
Tumour Biol; 2016 Mar; 37(3):2909-24. PubMed ID: 26409451
[TBL] [Abstract] [Full Text] [Related]
14. Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas.
Kruijff S; Sidhu SB; Sywak MS; Gill AJ; Delbridge LW
Ann Surg Oncol; 2014 Feb; 21(2):426-33. PubMed ID: 24081804
[TBL] [Abstract] [Full Text] [Related]
15. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
Witteveen JE; Hamdy NA; Dekkers OM; Kievit J; van Wezel T; Teh BT; Romijn JA; Morreau H
Mod Pathol; 2011 May; 24(5):688-97. PubMed ID: 21240254
[TBL] [Abstract] [Full Text] [Related]
16. The surgical strategy and the molecular analysis of patients with parathyroid cancer.
Enomoto K; Uchino S; Ito A; Watanabe S; Shibuya H; Enomoto Y; Noguchi S
World J Surg; 2010 Nov; 34(11):2604-10. PubMed ID: 20480190
[TBL] [Abstract] [Full Text] [Related]
17. [Parathyroid carcinoma].
Vieira JG; Ohe MN; Hauache OM; Oliveira UM; Delana JM; Gonçalves A; Lazaretti-Castro M
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):811-5. PubMed ID: 16444365
[TBL] [Abstract] [Full Text] [Related]
